Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]
Rhenman & Partners Asset Management AB boosted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 31.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,872 shares of the biopharmaceutical company’s stock after purchasing an additional 114,193 shares during the quarter. Rhenman […]
Revance Therapeutics (NASDAQ:RVNC) Price Target Lowered to $8.00 at The Goldman Sachs Group theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Needham & Company LLC Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $12.00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Blair William & Co. IL boosted its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 144.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 306,877 shares of the biopharmaceutical company’s stock after acquiring an additional 181,372 shares during […]